VA-REGULA
25.1.2024 08:01:35 CET | Business Wire | Press release
Before adopting an IDV system, it’s imperative to conduct thorough testing, especially for large-scale businesses. However, it is nearly impossible to obtain a reliable set of IDs with real NFC chips (as they contain sensitive personal data) to test-drive the verification process. Besides, it’s not that easy to test both positive and negative verification scenarios without representative ID sampling. Regula’s unique service, Regula NFC TestKit, effectively addresses these issues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240124863941/en/
An example of a test ID made for Regula NFC TestKit service customers (Photo: Business Wire)
Depending on the particular company’s business needs and market goals, Regula creates a test set of identity documents with NFC chips which are personalized with the data of fictitious identities or those provided by the customer. Apart from the chip, a visual zone and a machine readable zone (MRZ) can also be generated to enable robust cross-checking and system testing. These test IDs are simplified images (with special marks to show that they are not full replicas) of the required pages of the documents the company intends to verify. They are backed up with corresponding templates in a special database version so that the IDV solution can recognize them properly.
By choosing Regula NFC TestKit service, enterprises can benefit from:
- Shorter time to market. Checking and fine-tuning the IDV process with the help of test documents eliminates the necessity of undergoing an early adoption period during which a company could face friction.
- Enhanced IDV solution trial and early problem identification. Regula NFC TestKit service provides the most complete representation of identity documents with multiple data fields. That means any organization can test-drive the complete remote onboarding procedure to address potential issues or vulnerabilities.
- Flexibility and customization. Regula’s service is tailored to the specific needs of any given organization. It is possible to create an NFC-chip-based document sample of any type from any country to test the most likely customer onboarding scenarios.
- Maximum security assurance. Using NFC chips and replicating the data in the MRZ and visual zone ensures that IDV process testing mimics real-life scenarios to get ready to handle customers’ personal data securely.
To enable this service, Regula leverages its unique competencies in forensic examination, as well as IDV software and hardware development. The company personalizes NFC chips with fictitious persons’ data, which is recorded with the help of Regula’s document readers. Importantly, Regula generates all necessary certificate chains for every country in the list, signs the data using these certificates, and provides them to the customer for performing passive authentication. This approach fully imitates the scenario with real NFC chips in real IDs, which allows businesses to take advantage of lifelike document verification when testing their IDV systems.
Regula NFC TestKit is equipped with this functionality thanks to the fact that it is backed by the world’s most comprehensive identity document template database, which is exclusively owned and maintained by Regula. With more than 13,000 templates of IDs from 247 countries and territories, this database makes it possible to imitate nearly any identity document for testing purposes. And thanks to this asset, Regula is able to cover any geography a business may be interested in.
“Businesses currently strive to find suitable solutions to independently test the remote onboarding process of electronic documents, and until now, there have been no offerings on the market to address this gap. With our new service for complete imitation of real IDs, we enable organizations to conduct highly efficient testing to identify and prevent any potential issues prior to the launch of their IDV systems,” says Ihar Kliashchou, Chief Technology Officer at Regula.
Regula NFC TestKit service is provided exclusively for large enterprises that purchase the company’s software solutions. To learn more, contact Regula’s experts.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124863941/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
